Back to Glossary

Aromatase Inhibitors (AIs)

Aromatase inhibitors (AIs) are medications that block the enzyme aromatase, which converts androgens into estrogen.

Aromatase inhibitors (AIs) are medications that block the enzyme aromatase, which converts androgens into estrogen. Since they lower estrogen levels, AIs are commonly used to treat hormone receptor–positive breast cancer, particularly in postmenopausal women. Examples of AI medications include anastrozole, letrozole, and exemestane. Inline content unavailable

Why it matters :

Aromatase inhibitors (AIs) play a key role in breast cancer treatment for postmenopausal women by significantly reducing estrogen levels. However, this suppression increases the risk of side effects related to estrogen deficiency, including:

  • Accelerated bone loss, leading to osteoporosis and fractures

  • Arthralgia (joint pain) and myalgia (muscle pain), which affect physical function

  • Genitourinary syndrome of menopause which can result in vaginal dryness, pain with sex and an increased risk for urinary tract infections

  • High rates of treatment discontinuation, especially in the first year of therapy

According to a 2020 review, up to 20–30% of patients discontinue AIs due to intolerable side effects, and fracture risk increases significantly without preventive care. Effective symptom monitoring and supportive strategies are crucial to help patients complete therapy.Inline content unavailable

How Amissa Helps:

Amissa provides women on aromatase inhibitors with personalized support by allowing them to:

  • Track common AI side effects such as joint pain, hot flashes, fatigue, mood swings, and vaginal dryness

  • Log bone health metrics, including DEXA scan results, calcium/vitamin D intake, and fall risk factors

  • Record medication adherence, missed doses, or reasons for discontinuation

  • Sync wearable data (e.g., step count, sleep, activity level) to monitor how symptoms affect daily life

  • Generate provider-ready reports that summarize side effects and treatment adherence over time

By capturing this data, Amissa helps users and clinicians:

  • Identify symptom patterns to tailor your care with non-hormonal prescriptions and lifestyle recommendations (e.g., physical therapy, vaginal lubricants)

  • Intervene early to reduce risk of treatment drop-off

  • Optimize bone protection strategies, such as bisphosphonates, weight-bearing exercise, and dietary support

  • use provider-ready reports to facilitate collaborative, evidence-based decisions across oncology, gynecology, and primary care Inline content unavailable

Back to Glossary